# leukemia (blogs) — RSS Amplifier Recent posts from the 4 feeds in the RSS Amplifier directory that cover leukemia. Page: Feed: --- ## [Partnership expands access to CLL treatment in low-, middle-income countries](https://sohoinsider.com/news/partnership-expands-access-to-cll-treatment-in-low-middle-income-countries/?utm_source=rss&utm_medium=rss&utm_campaign=partnership-expands-access-to-cll-treatment-in-low-middle-income-countries) _2026-08-20 · SOHO Insider Editors · SOHO Insider_ To date, the initiative has enabled access to the treatment for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding its original scope by about 150 patients. The post Partnership expands access to CLL treatment in low-, middle-income countries appeared first on SOHO Insider . ## [Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN](https://sohoinsider.com/leukemia/phase-1-data-reported-for-anti-cd123-car-t-cell-therapy-in-relapsed-or-refractory-aml-bpdcn/?utm_source=rss&utm_medium=rss&utm_campaign=phase-1-data-reported-for-anti-cd123-car-t-cell-therapy-in-relapsed-or-refractory-aml-bpdcn) _2026-08-19 · Patrick Daly · SOHO Insider_ The study’s authors, led by Lihua E Budde, MD, PhD, of City of Hope in Duarte, California, published the findings in the Journal of Hematology & Oncology. The post Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN appeared first on SOHO Insider . ## [Drs. George Lenz and Loretta Nastoupil discuss phase 3 FRONTMIND study](https://sohoinsider.com/lymphoma/drs-george-lenz-and-loretta-nastoupil-discuss-phase-3-frontmind-study/?utm_source=rss&utm_medium=rss&utm_campaign=drs-george-lenz-and-loretta-nastoupil-discuss-phase-3-frontmind-study) _2026-08-18 · Leah Sherwood · SOHO Insider_ From EHA 2026, Dr. Loretta Nastoupil interviews Dr. Georg Lenz on the phase 3 FRONTMIND study, a randomised, double-blind, placebo-controlled study that evaluated tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma. The post Drs. George Lenz and Loretta Nastoupil discuss phase 3 FRONTMIND study appeared first on… ## [FDA grants accelerated approval to iberdomide combo in multiple myeloma](https://sohoinsider.com/news/fda-grants-accelerated-approval-to-iberdomide-combo-in-multiple-myeloma/?utm_source=rss&utm_medium=rss&utm_campaign=fda-grants-accelerated-approval-to-iberdomide-combo-in-multiple-myeloma) _2026-08-14 · SOHO Insider Editors · SOHO Insider_ ...the approval is based on results from the Phase 3 EXCALIBER-RRMM trial, which showed iberdomide significantly improved minimal residual disease (MRD)-negative complete response (CR) rates. The post FDA grants accelerated approval to iberdomide combo in multiple myeloma appeared first on SOHO Insider . ## [Post-transplantation outcomes have improved for Hodgkin lymphoma](https://sohoinsider.com/lymphoma/post-transplantation-outcomes-have-improved-for-hodgkin-lymphoma/?utm_source=rss&utm_medium=rss&utm_campaign=post-transplantation-outcomes-have-improved-for-hodgkin-lymphoma) _2026-08-14 · Leah Sherwood · SOHO Insider_ The improved post-transplantation outcomes are likely due to the introduction of novel therapeutic agents, alongside advances in donor selection, conditioning regimens, and graft-versus-host disease prophylaxis, the authors suggested. The post Post-transplantation outcomes have improved for Hodgkin lymphoma appeared first on SOHO Insider . ## [Fedratinib demonstrates favorable OS in MDS/MPN overlap syndrome](https://sohoinsider.com/myeloproliferative-neoplasms/fedratinib-demonstrates-favorable-os-in-mds-mpn-overlap-syndrome/?utm_source=rss&utm_medium=rss&utm_campaign=fedratinib-demonstrates-favorable-os-in-mds-mpn-overlap-syndrome) _2026-08-11 · SOHO Insider Editors · SOHO Insider_ The results showed a 30% spleen response rate and a 47% symptom response rate among evaluable patients. Overall survival reached around 37 months, which compares favorably to historical controls where survival is typically between one and three years. The post Fedratinib demonstrates favorable OS in MDS/MPN overlap syndrome appeared first on SOHO Insider . ## [NICE recommends acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukemia](https://sohoinsider.com/news/nice-recommends-acalabrutinib-for-mantle-cell-lymphoma-chronic-lymphocytic-leukemia/?utm_source=rss&utm_medium=rss&utm_campaign=nice-recommends-acalabrutinib-for-mantle-cell-lymphoma-chronic-lymphocytic-leukemia) _2026-08-11 · SOHO Insider Editors · SOHO Insider_ The draft guidance expands frontline options for patients who are ineligible for stem cell transplants or who require oral therapies. The post NICE recommends acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukemia appeared first on SOHO Insider . ## [FDA approves subcutaneous isatuximab-irfc for multiple myeloma](https://sohoinsider.com/news/fda-approves-subcutaneous-isatuximab-irfc-for-multiple-myeloma/?utm_source=rss&utm_medium=rss&utm_campaign=fda-approves-subcutaneous-isatuximab-irfc-for-multiple-myeloma) _2026-08-11 · SOHO Insider Editors · SOHO Insider_ Isatuximab-irfc is currently approved across three indications in the US, including in combination with bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant, Sanofi reported in the release. The post FDA approves subcutaneous isatuximab-irfc for multiple myeloma appeared first on SOHO Insider . ## [ASCO and EHA 2026 updates on the third-gen TKI olverembatinib](https://sohoinsider.com/leukemia/asco-and-eha-2026-updates-on-the-third-gen-tki-olverembatinib/?utm_source=rss&utm_medium=rss&utm_campaign=asco-and-eha-2026-updates-on-the-third-gen-tki-olverembatinib) _2026-08-11 · SOHO Insider Editors · SOHO Insider_ Dr. Jabbour details safety and efficacy findings for an olverembatinib plus blinatumomab combination in leukemia. The post ASCO and EHA 2026 updates on the third-gen TKI olverembatinib appeared first on SOHO Insider . ## [Global KMT2A MRD testing launched for AML,ALL](https://sohoinsider.com/news/global-kmt2a-mrd-testing-launched-for-aml-all/?utm_source=rss&utm_medium=rss&utm_campaign=global-kmt2a-mrd-testing-launched-for-aml-all) _2026-08-10 · SOHO Insider Editors · SOHO Insider_ The standardized assay targets common KMT2A partner fusion genes to support disease characterization and longitudinal monitoring in menin inhibitor clinical trials. The post Global KMT2A MRD testing launched for AML,ALL appeared first on SOHO Insider . ## [Accept your Doppler invite (Sponsored)](https://crawlproof.com/a/CVhh159BaoRE) _2026-08-10 · **Sponsored**_ Create your Doppler account using the invite code you received. ## [The instability of the modern workforce is killing us](https://codegregg.com/posts/the-instability-of-the-modern-workforce-is-killing-us/) _2026-08-01 · Matt Gregg — Software Engineer — Journal_ We’ve been living inside this for years. The schedules that change week to week. The review meetings where the target moves every quarter. The sudden reorg. The layoff email. The hiring freeze that somehow still expects you to cover two departed coworkers’ jobs for the same salary. It’s not one bad company or one bad year. It’s a pattern. And companies of the future are eventually going to have to… ## [Why does management fear people who give a fuck?](https://codegregg.com/posts/why-does-management-fear-people-who-give-a-fuck/) _2026-04-07 · Matt Gregg — Software Engineer — Journal_ Me: Why is it that management in companies fear those who give a fuck? ChatGPT: Short answer: because people who give a fuck are hard to control. Longer answer (from the inside of organizations): They expose bullshit Someone who cares notices contradictions, broken processes, wasted effort, and empty slogans. They ask why. That threatens fragile narratives like “everything’s fine” or “this is just… ## [Build Mode: Seven launches in one creative streak](https://codegregg.com/posts/build-mode-seven-launches-in-one-creative-streak/) _2026-03-14 · Matt Gregg — Software Engineer — Journal_ Build Mode Seven things I shipped (and a couple I quietly made) Lately I’ve been in that particular kind of flow where ideas don’t wait for permission (you can check out my other post about that here ). Something sounds interesting, I open a repo, and a few hours later there’s a thing that didn’t exist before. Here’s the tour ↓ Project What it is Links Horizon Local-first long-term goal journal… ## [NAS Learnings: From Zettlab to UnRaid and necessary apps for your setup](https://codegregg.com/posts/nas-learnings-from-zettlab-to-unraid-and-necessary-apps-for-your-setup/) _2026-02-23 · Matt Gregg — Software Engineer — Journal_ The Self-Hosted Journey: What I Learned Building My Home NAS TL;DR: I backed the Zettlab 4-bay NAS and, while I’m a huge fan of their hardware and mission, I’ve found my stride using Docker containers for most tasks. If I were starting from scratch today, I’d likely build an UnRaid server on a gaming PC to consolidate my gaming and hosting into one machine. My Must-Have Apps: Jellyfin (Video… ## [Side projects](https://codegregg.com/posts/side-projects/) _2026-01-21 · Matt Gregg — Software Engineer — Journal_ You know that feeling when you're lying in bed and an idea pops into your head? Maybe it's a tool that would make your life slightly easier, or a way to help people organize, or something that could bring people together. Before, those ideas would just rattle around in my brain until I forgot about them or they got pushed out by work priorities. When I was laid off from my position at Shopify in… ## [SamE](https://www.accbf.org/SamE.html) _2025-03-10 · American Childrens Cancer Benevolence Fund Updates_ learn about Sam's battle with High Risk Neuroblastoma ## [Hidden Struggles of Families Battling Childhood Cancer](https://www.accbf.org/Hidden-Struggles-of-Families-Battling-Childhood-Cancer.html) _2024-12-10 · American Childrens Cancer Benevolence Fund Updates_ Imagine hearing the words no parent ever wants to hear: "Your child has cancer." In that moment, the world stops. The walls close in ## [Izabella Phoenix Eckhardt Obituary](https://www.accbf.org/Izabella-Phoenix-Eckhardt.html) _2024-12-10 · American Childrens Cancer Benevolence Fund Updates_ Izabella Phoenix Eckhardt Obituary ## [Jack's Story](https://www.accbf.org/Jacks-Story.html) _2024-12-10 · American Childrens Cancer Benevolence Fund Updates_ Jack's story is a powerful testament to resilience and the strength of family bonds in the face of unimaginable challenges ## [Karter](https://www.accbf.org/Karter.html) _2024-11-18 · American Childrens Cancer Benevolence Fund Updates_ Learn about Karter's battle with Osteosarcoma of the Humerus ## [Trade Smarter With IBKR (Sponsored)](https://crawlproof.com/a/91n7lTSbf4Fq) _2024-11-18 · **Sponsored**_ Join Interactive Brokers through a referral and access low-cost global trading. ## [Navigating the Adderall Prescription Maze in 2024: A Monthly Adventure](https://codegregg.com/posts/navigating-the-adderall-prescription-maze-in-2024-a-monthly-adventure/) _2024-10-22 · Matt Gregg — Software Engineer — Journal_ Understanding Walgreens’ Adderall Refill Policy Ah, the intricacies of modern healthcare! If you've ever journeyed through the process of refilling your Adderall XR prescription, you know it’s not a straightforward task. Each month, as my supply dwindles, I brace for another round of challenges—think of it as a quest for a rare treasure rather than a simple chore. The Automated System Struggle… ## [Gatsby Dark Mode with Themes](https://codegregg.com/posts/gatsby-dark-mode-with-themes/) _2024-10-21 · Matt Gregg — Software Engineer — Journal_ Implementing Dark Mode in GatsbyJS 4.7 With the release of GatsbyJS 4.7, developers now have more tools and features at their disposal to create dynamic and responsive websites. One popular feature that can significantly enhance user experience is the ability to toggle between light and dark modes. This feature not only adds aesthetic appeal but also helps reduce eye strain and conserve battery…